Beetroot juice and walking ability in peripheral artery disease
Tests beetroot juice on walking in people with peripheral artery disease.
Key facts
- Who runs it
- Northwestern University
- Where
- Charlottesville, Chicago, and Minneapolis, United StatesSee the 4 sites
- Trial code
- Registry title
- BEETroot Juice to Reverse Functional Impairment in PAD
- Status
- Recruiting
- People taking part
- 210 people, planned
- Started
- 25 Jan 2023
- Expected to end
- 1 Oct 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Beetroot juice
- Placebo
- Record updated
- 15 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 or older with peripheral artery disease (narrowed leg arteries). It tests whether beetroot juice, compared to a placebo drink, helps them walk farther.
- Age
- 50 years and older
- Sex
- All sexes
- Disease stage
- Peripheral artery disease shown by an ankle brachial index (ABI) <= 0.90, vascular lab or angiography tests (such as toe brachial pressure <= 0.70 or at least 70% narrowing of a leg artery), or an ABI of >0.90 and <=1.00 with a 20% or greater drop after a heel-rise test. Six-minute walk distance must be 500 to 1600 feet.
- Earlier treatment
- No major surgery, heart or leg artery procedure, or major heart event in the previous three months. No supervised treadmill exercise program or clinical trial in the previous three months. No beetroot juice, beetroot supplements, oral nitrate or nitrite for 30 days before testing and during the trial.
- Biomarker or test result
- eGFR must not be <30 and potassium must not be >5.0. Blood pressure must not be <100/45.
Main reasons for not taking part
- Leg amputation above or below the knee, or severe leg ischemia (ABI <0.40 with pain at rest)
- Needing a wheelchair or walker, or walking limited by something other than PAD
- Foot ulcer on the bottom of the foot
- Serious illness such as lung disease needing oxygen, Parkinson's disease, or cancer treated in the previous two years
- Mini-Mental Status Examination (MMSE) score < 23, or not speaking English
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Age 50 and older
- Presence of peripheral artery disease, defined as:; An ankle brachial index (ABI) <= 0.90 at baseline; Vascular lab evidence of PAD (such as a toe brachial pressure <= 0.70 or an ankle brachial index <=0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities; An ABI of >0.90 and <=1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test
Who cannot take part
- Planned major surgery, coronary or leg revascularization during the next five months
- Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
- Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.]
- Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and/or unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial
- Currently consuming one cup or more of beets daily. Participants will be asked to discontinue beet ingestion of one cup or more of beets for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial
- Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.]
- Participation in a supervised treadmill exercise program in previous three months
- Current foot ulcer on bottom of foot
- Failure to successfully complete the study run-in
- Allergy to beetroot juice
- Visual impairment that limits walking ability
- History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial
- An eGFR value <30 or potassium >5.0
- Above- or below-knee amputation
- Critical limb ischemia defined as an ABI <0.40 with symptoms of rest pain
- Wheelchair confinement or requiring a walker to ambulate
- Walking is limited by a symptom other than PAD
- Mini-Mental Status Examination (MMSE) score < 23
- Non-English speaking
- Six-minute walk distance of <500 feet or >1600 feet. Investigator discretion will be used to decide whether participants who walk greater than 1600 feet are eligible
- Baseline blood pressure <100/45
- Using an antibacterial mouthwash (such as Cepacol) or a mouthwash containing chlorhexidine and unwilling to discontinue
- In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant
Where in United States
- University of VirginiaCharlottesville, United StatesContact: Mary McDermott, MDNo longer taking part
- Northwestern University Feinberg School of MedicineChicago, United StatesContact: Kathryn Domanchuk, BSTaking people
- University of ChicagoChicago, United StatesContact: Tamar Polonsky, MDTaking people
- University of MinnesotaMinneapolis, United StatesContact: Diane Treat-Jacobson, PhDTaking people
About the trial
What the trial wants to find out
The BEET PAD Trial is a multi-centered double-blind randomized clinical trial designed to determine whether beetroot juice, compared to placebo, improves six-minute walk distance at four month follow-up in people with lower extremity peripheral artery disease (PAD). Investigators hypothesize that by simultaneously increasing lower extremity perfusion, gastrocnemius muscle mitochondrial activity, and myofiber health and regeneration, beetroot juice will significantly improve walking performance in people with PAD. The primary aim is to determine whether beetroot juice significantly improves six-minute walk distance at 4-month follow-up in people with PAD, compared to placebo. Preliminary evidence suggests that beetroot juice has both acute and chronic effects on walking performance in PAD. The primary outcome will measure the combined acute and chronic effect of beetroot juice (i.e. the maximal effect) on change in 6-minute walk at 4-month follow-up. In secondary aims, investigators will distinguish between acute and chronic effects of beetroot juice on six-minute walk and delineate biologic pathways by which beetroot juice improves walking performance in PAD, by measuring change in gastrocnemius muscle perfusion (MRI arterial spin labeling) and gastrocnemius muscle health. The trial will assess the durability of beetroot juice effects on six-minute walk. Nitrate in beetroot juice is metabolized to nitrite and subsequently to NO, attaining peak nitrite levels 2.5 hours after ingestion. The trial will determine whether a higher peak or a greater increase in plasma nitrite at 2.5 hours after beetroot juice consumption at baseline has a greater effect on six-minute walk at 4-month follow-up, compared to a lower peak or a smaller increase, respectively.
The 2 groups in the trial
- Beetroot juiceExisting treatment, for comparison
The beetroot juice intervention comes in a single 70 ml drink and is manufactured by James White Drinks. Each drink contains beetroot juice and 2% lemon juice, made from concentrates. Each serving of 70 mL of beetroot juice contains 400 mgs (6.45 millimoles) of nitrate and will be taken twice daily for a total daily dose of 800 mgs (12.90 millimoles) of nitrate.
- PlaceboPlacebo, for comparison
The placebo comes in a single 70 ml drink and is manufactured by James White Drinks. The placebo contains beetroot juice and 2% lemon juice, made from concentrates, and is filtered to remove nitrate.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- BEETroot Juice to Reverse Functional Impairment in PAD: The BEET PAD Trial
- Plain-language title
- Beetroot juice and walking ability in peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Record updated
- 15 April 2026